Abstract:Intravesical administration of BCG was the first immunotherapy approved by the FDA and it is still nowadays the treatment of choice for a subset of non-muscle invasive bladder cancer patients. Considering this precedent and the strong capabilities of BCG to trigger cellular responses, we hypothesized that systemic administration of BCG by the intravenous route (IV BCG), a vaccination strategy that has been found well-tolerated, highly immunogenic and effective at preventing tuberculosis infection in non-human … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.